VP1 amino acid residue 145 of enterovirus 71 is a key residue for its receptor attachment and resistance to neutralizing antibody during cynomolgus monkey infection

Journal of Virology

Volumn 92, Issue 15, 2018, Pages

  Fujii, Ken ^a   Sudaka, Yui ^a   Takashino, Ayako ^a   Kobayashi, Kyousuke ^a   Kataoka, Chikako ^b   Suzuki, Tadaki ^b   Iwata Yoshikawa, Naoko ^b   Kotani, Osamu ^b   Ami, Yasushi ^b   Shimizu, Hiroyuki ^b   Nagata, Noriyo ^b   Mizuta, Katsumi ^c   Matsuzaki, Yoko ^d   Koike, Satoshi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c YAMAGATA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

Author keywords

Animal models; Enterovirus; Neutralizing antibodies; Pathogenesis

Indexed keywords

AMINO ACID; CYTOKINE; NEUTRALIZING ANTIBODY; PROTEIN VP1; VIRUS RECEPTOR; VIRUS RNA; CAPSID PROTEIN; HEPARAN SULFATE; VIRUS ANTIBODY;

AMINO ACID ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; ENTEROVIRUS A71; ENTEROVIRUS INFECTION; GENETIC STABILITY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SYMPTOM; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; VIRUS VIRULENCE; AMINO ACID SUBSTITUTION; ANIMAL; CHLOROCEBUS AETHIOPS; COMPARATIVE STUDY; CV-1 CELL LINE; ENTEROVIRUS A; GENETICS; IMMUNOLOGY; METABOLISM; PATHOGENICITY; VERO CELL LINE; VETERINARY MEDICINE; VIROLOGY; VIRULENCE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; COS CELLS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HEPARITIN SULFATE; MACACA FASCICULARIS; MALE; VERO CELLS; VIRULENCE;

EID: 85050160488     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00682-18     Document Type: Article

References (60)

1. Pallansch M, Oberste MS, Whitton JL. 2013. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p 490-530. In Knipe D, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA
2. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus
3. Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424-429. https:// doi.org/10.1038/nsmb.2255
4. Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal structure of human enterovirus 71. Science 336:1274. https://doi.org/10.1126/science.1218713
5. Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K, Koike S. 2012. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol 86:5686-5696. https://doi.org/10.1128/JVI.00020-12
6. Yamayoshi S, Ohka S, Fujii K, Koike S. 2013. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 87:3335-3347. https://doi.org/10.1128/JVI.02070-12
7. Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, Wu X, Yao X, Mao Q, Li X, Dong W, Wan X, Huang N, Shen X, Liang Z, Li W. 2012. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem 287:6406-6420. https://doi.org/10.1074/jbc.M111.301622
8. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15:794-797. https://doi.org/10.1038/nm.1961
9. Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611-620. https://doi.org/10.1128/JVI.02226-12
10. Yang SL, Chou YT, Wu CN, Ho MS. 2011. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol 85:11809-11820. https://doi.org/10.1128/JVI.00297-11
11. Su PY, Liu YT, Chang HY, Huang SW, Wang YF, Yu CK, Wang JR, Chang CF. 2012. Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. BMC Microbiol 12:162. https://doi.org/10.1186/1471-2180-12-162
12. Su PY, Wang YF, Huang SW, Lo YC, Wang YH, Wu SR, Shieh DB, Chen SH, Wang JR, Lai MD, Chang CF. 2015. Cell surface nucleolin facilitates enterovirus 71 binding and infection. J Virol 89:4527-4538. https://doi.org/10.1128/JVI.03498-14
13. Du N, Cong H, Tian H, Zhang H, Zhang W, Song L, Tien P. 2014. Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol 88:5816-5833. https://doi.org/10.1128/JVI.03826-13
14. Yamayoshi S, Fujii K, Koike S. 2014. Receptors for enterovirus 71. Emerg Microbes Infect 3:e53. https://doi.org/10.1038/emi.2014.49
15. Sarrazin S, Lamanna WC, Esko JD. 2011. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3:a004952. https://doi.org/10.1101/ cshperspect.a004952
16. Nishimura Y, Lee H, Hafenstein S, Kataoka C, Wakita T, Bergelson JM, Shimizu H. 2013. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog 9:e1003511. https://doi.org/10.1371/journal.ppat.1003511
17. Tan CW, Sam IC, Lee VS, Wong HV, Chan YF. 2017. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology 501:79-87. https://doi.org/10.1016/j.virol.2016.11.009
18. Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC. 2008. The molecular basis of mouse adaptation by human enterovirus 71. J Gen Virol 89:1622-1632. https://doi.org/10.1099/vir.0.83676-0
19. Wang W, Duo J, Liu J, Ma C, Zhang L, Wei Q, Qin C. 2011. A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect 13:862-870. https://doi.org/10.1016/j.micinf.2011.04.004
20. Arita M, Ami Y, Wakita T, Shimizu H. 2008. Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is es-sential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol 82:1787-1797. https://doi.org/10.1128/JVI.01798-07
21. Huang SW, Wang YF, Yu CK, Su IJ, Wang JR. 2012. Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology 422:132-143. https://doi.org/10.1016/j.virol.2011.10.015
22. Zaini Z, McMinn P. 2012. A single mutation in capsid protein VP1 (Q145E) of a genogroup C4 strain of human enterovirus 71 generates a mousevirulent phenotype. J Gen Virol 93:1935-1940. https://doi.org/10.1099/ vir.0.043893-0
23. Kataoka C, Suzuki T, Kotani O, Iwata-Yoshikawa N, Nagata N, Ami Y, Wakita T, Nishimura Y, Shimizu H. 2015. The role of VP1 amino acid residue 145 of enterovirus 71 in viral fitness and pathogenesis in a cynomolgus monkey model. PLoS Pathog 11:e1005033. https://doi.org/ 10.1371/journal.ppat.1005033
24. Li R, Zou Q, Chen L, Zhang H, Wang Y. 2011. Molecular analysis of virulent determinants of enterovirus 71. PLoS One 6:e26237. https://doi.org/10.1371/journal.pone.0026237
25. Chang SC, Li WC, Chen GW, Tsao KC, Huang CG, Huang YC, Chiu CH, Kuo CY, Tsai KN, Shih SR, Lin TY. 2012. Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative analysis of complete genomes. J Med Virol 84:931-939. https://doi.org/10.1002/jmv.23287
26. Liu Y, Fu C, Wu S, Chen X, Shi Y, Zhou B, Zhang L, Zhang F, Wang Z, Zhang Y, Fan C, Han S, Yin J, Peng B, Liu W, He X. 2014. A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in mainland China. Virus Genes 48:260-272. https://doi.org/10.1007/ s11262-014-1035-2
27. Zhang B, Wu X, Huang K, Li L, Zheng L, Wan C, He ML, Zhao W. 2014. The variations of VP1 protein might be associated with nervous system symptoms caused by enterovirus 71 infection. BMC Infect Dis 14:243. https://doi.org/10.1186/1471-2334-14-243
28. Kobayashi K, Sudaka Y, Takashino A, Imura A, Fujii K, Koike S. 2018. Amino acid variation at VP1-145 of enterovirus 71 determines attachment receptor usage and neurovirulence in human scavenger receptor B2 transgenic mice. J Virol 92:e00681-18. https://doi.org/10.1128/JVI.00681-18
29. Hagiwara A, Yoneyama T, Hashimoto I. 1983. Isolation of a temperaturesensitive strain of enterovirus 71 with reduced neurovirulence for monkeys. J Gen Virol 64:499-502. https://doi.org/10.1099/0022-1317-64-2-499
30. Hashimoto I, Hagiwara A. 1982. Pathogenicity of a poliomyelitis-like disease in monkeys infected orally with enterovirus 71: a model for human infection. Neuropathol Appl Neurobiol 8:149-156. https://doi.org/10.1111/j.1365-2990.1982.tb00269.x
31. Hashimoto I, Hagiwara A. 1982. Studies on the pathogenesis of and propagation of enterovirus 71 in poliomyelitis-like disease in monkeys. Acta Neuropathol 58:125-132. https://doi.org/10.1007/BF00691653
32. Hashimoto I, Hagiwara A, Kodama H. 1978. Neurovirulence in cynomolgus monkeys of enterovirus 71 isolated from a patient with hand, foot and mouth disease. Arch Virol 56:257-261. https://doi.org/10.1007/ BF01317855
33. Nagata N, Shimizu H, Ami Y, Tano Y, Harashima A, Suzaki Y, Sato Y, Miyamura T, Sata T, Iwasaki T. 2002. Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol 67:207-216. https://doi.org/10.1002/jmv.2209
34. Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, Suzaki Y, Sato Y, Hasegawa H, Sata T, Miyamura T, Shimizu H. 2004. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 85:2981-2989. https://doi.org/10.1099/vir.0.79883-0
35. Cellier C, Foray S, Hermine O. 2000. Regional enteritis associated with enterovirus in a patient with X-linked agammaglobulinemia. N Engl J Med 342:1611-1612. https://doi.org/10.1056/NEJM200005253422113
36. Mease PJ, Ochs HD, Wedgwood RJ. 1981. Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. N Engl J Med 304:1278-1281. https://doi.org/10.1056/NEJM198105213042107
37. Nathanson N, Bodian D. 1962. Experimental poliomyelitis following intramuscular virus injection. III. The effect of passive antibody on paralysis and viremia. Bull Johns Hopkins Hosp 111:198-220
38. WHO. 2011. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). WHO, Geneva, Switzerland
39. Gwaltney JM, Jr, Calhoun AM. 1970. Viral aggregation resulting in the failure to correctly identify an unknown rhinovirus. Appl Microbiol 20: 390-392
40. Ida-Hosonuma M, Iwasaki T, Yoshikawa T, Nagata N, Sato Y, Sata T, Yoneyama M, Fujita T, Taya C, Yonekawa H, Koike S. 2005. The alpha/ beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 79:4460-4469. https://doi.org/10.1128/JVI.79.7.4460-4469.2005
41. Bernard KA, Klimstra WB, Johnston RE. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93-103. https://doi.org/10.1006/viro.2000.0546
42. Lee E, Wright PJ, Davidson A, Lobigs M. 2006. Virulence attenuation of dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J Gen Virol 87:2791-2801. https://doi.org/10.1099/vir.0.82164-0
43. Lee E, Hall RA, Lobigs M. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J Virol 78:8271-8280. https://doi.org/10.1128/JVI.78.15.8271-8280.2004
44. Lee E, Lobigs M. 2002. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J Virol 76:4901-4911. https://doi.org/10.1128/ JVI.76.10.4901-4911.2002
45. Wang Y, Pfeiffer JK. 2016. Emergence of a large-plaque variant in mice infected with coxsackievirus B3. mBio 7:e00119. https://doi.org/10.1128/ mBio.00119-16
46. Anez G, Men R, Eckels KH, Lai CJ. 2009. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J Virol 83:10384-10394. https://doi.org/10.1128/JVI.01083-09
47. Nickells J, Cannella M, Droll DA, Liang Y, Wold WS, Chambers TJ. 2008. Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model. J Virol 82:12510-12519. https://doi.org/ 10.1128/JVI.00458-08
48. Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, Meixner T, Heinz FX. 2001. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol 75:5627-5637. https://doi.org/10.1128/JVI.75.12.5627-5637.2001
49. Silva LA, Khomandiak S, Ashbrook AW, Weller R, Heise MT, Morrison TE, Dermody TS. 2014. A single-amino-acid polymorphism in chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization. J Virol 88:2385-2397. https://doi.org/10.1128/JVI.03116-13
50. Ashbrook AW, Burrack KS, Silva LA, Montgomery SA, Heise MT, Morrison TE, Dermody TS. 2014. Residue 82 of the chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice. J Virol 88:12180-12192. https://doi.org/10.1128/JVI.01672-14
51. Gardner CL, Hritz J, Sun C, Vanlandingham DL, Song TY, Ghedin E, Higgs S, Klimstra WB, Ryman KD. 2014. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 8:e2719. https:// doi.org/10.1371/journal.pntd.0002719
52. Ryman KD, Klimstra WB, Johnston RE. 2004. Attenuation of Sindbis virus variants incorporating uncleaved PE2 glycoprotein is correlated with attachment to cell-surface heparan sulfate. Virology 322:1-12. https:// doi.org/10.1016/j.virol.2004.01.003
53. Klimstra WB, Ryman KD, Johnston RE. 1998. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol 72:7357-7366
54. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P. 2011. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 29: 4362-4372. https://doi.org/10.1016/j.vaccine.2011.04.010
55. Dowd KA, DeMaso CR, Pierson TC. 2015. Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing. mBio 6:e01559-15. https://doi.org/10.1128/mBio.01559-15
56. Kolawole AO, Smith HQ, Svoboda SA, Lewis MS, Sherman MB, Lynch GC, Pettitt BM, Smith TJ, Wobus CE. 2017. Norovirus escape from broadly neutralizing antibodies is limited to allostery-like mechanisms. mSphere 2:e00334-17. https://doi.org/10.1128/mSphere.00334-17
57. Lindesmith LC, Mallory ML, Debbink K, Donaldson EF, Brewer-Jensen PD, Swann EW, Sheahan TP, Graham RL, Beltramello M, Corti D, Lanzavecchia A, Baric RS. 2018. Conformational occlusion of blockade antibody epitopes, a novel mechanism of GII.4 human norovirus immune evasion. mSphere 3:e00518-17. https://doi.org/10.1128/mSphere.00518-17
58. Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H. 2007. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81: 9386-9395. https://doi.org/10.1128/JVI.02856-06
59. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71 Nat Med 15:798-801. https://doi.org/10.1038/nm.1992
60. Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, Itagaki T, Ohmi A, Okamoto M, Nishimura H, Matsuzaki Y, Hongo S, Sugawara K, Shimizu H, Ahiko T. 2009. Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 27:3153-3158. https://doi.org/10.1016/j.vaccine.2009.03.060